Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Agios Pharmaceuticals Inc | AGIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 36.58 | 0.00 | 0.00 | 0.00 | 36.58 | 06:59:54 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.01 | 47.00 | 46.99 | 99.98% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Agios Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.15B | 58.75M | $ -346.03M | -6.03 | - | 57.95M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Agios Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGIO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 35.68 | 38.9 | 35.51 | 37.7142 | 645k | 0.9 | 2.52% |
| 1 Month | 43.61 | 43.75 | 33.17 | 37.2587 | 539k | -7.03 | -16.12% |
| 3 Months | 49.72 | 51.09 | 33.17 | 42.3155 | 546k | -13.14 | -26.43% |
| 6 Months | 65.02 | 69.64 | 33.17 | 48.6737 | 526k | -28.44 | -43.74% |
| 1 Year | 72.01 | 79.17 | 33.17 | 54.1463 | 524k | -35.43 | -49.20% |
| 3 Years | 46.9 | 99.8242 | 33.17 | 59.1150 | 515k | -10.32 | -22.00% |
| 5 Years | 47.73 | 138.85 | 33.17 | 66.6173 | 591k | -11.15 | -23.36% |
Agios Pharmaceuticals Description
| Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
